Please login to the form below

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

FDA rejects GSK’s Nucala for COPD

There was bad if not unexpected news for GlaxoSmithKline late Friday, after the FDA refused to extend the indications of its asthma drug Nucala to include chronic obstructive pulmonary disorder (COPD). ... Meanwhile, Nucala isn’t the first drug in the

Latest news

FDA rejects GSK’s Nucala for COPD

There was bad if not unexpected news for GlaxoSmithKline late Friday, after the FDA refused to extend the indications of its asthma drug Nucala to include chronic obstructive pulmonary disorder (COPD). ... Meanwhile, Nucala isn’t the first drug in the
AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’ s first-in-class asthma drug gets breakthrough status. The IL-5 inhibitor is already approved for severe asthma in the EU. ... AstraZeneca and partner Amgen have picked up a breakthrough designation from the FDA for tezepelumab, a drug that
New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... Other bright spots for AZ included the continued growth if
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances for eosinophilic asthma, when usual therapies
PMCPA takes AZ to task over asthma drug press release

PMCPA takes AZ to task over asthma drug press release. Concluded that the data in the release had not been “placed in context”. ... A complaint filed by GlaxoSmithKline against AstraZeneca about a press release for its severe asthma drug Fasenra,

More from news
Approximately 2 fully matching, plus 123 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
US health reforms

In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
Building BRICs: pharma's key emerging markets are becoming giants

In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Enterprise Therapeutics appoints CEO

Enterprise Therapeutics appoints CEO. Dr John Ford will lead the UK drug discovery company. ... He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.
Former RBS head takes the reins as GSK chair

the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Healthcare PR Senior Account Manager: Salary TBC

Senior Medical Writer: Salary is DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Associate Scientific Director: Salary TBC

Systematic Review Lead- London: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Manager- 4 days per week or full-time: Salary TBC

Graduate Scientific Editor: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Market Access Consultant - Greater Manchester: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Subscribe to our email news alerts

PMHub

Add my company

Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....